Sort   by:  
 Page size 
UnknownNew Treatment Options for Pancreatic Neuroendocrine Tumors: A Narrative Review.
Not available
S-EPMC12691000 | biostudies-literature
UnknownCurrent State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges.
Not available
S-EPMC9201309 | biostudies-literature
UnknownWhat is new about ovarian malignancies?
Not available
S-EPMC8768052 | biostudies-literature
UnknownNew Treatment Options in Metastatic Pancreatic Cancer.
Not available
S-EPMC10136527 | biostudies-literature
UnknownA multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.
Not available
S-EPMC5943284 | biostudies-literature
UnknownAMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
Not available
S-EPMC4666535 | biostudies-literature
UnknownPreparation and Characterization of New pH-Sensitive Polyurethane Hydrogels as Anti-Cancer Drug Delivery Systems for 5-Fluorouracyl and Fluorodeoxyuridine.
Not available
S-EPMC12609683 | biostudies-literature
UnknownFirst-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Not available
S-EPMC7154735 | biostudies-literature
UnknownMonitoring of prostate cancer screening in the European Union: development of key performance indicators through the PRAISE-U project.
Not available
S-EPMC11804572 | biostudies-literature
UnknownHealth Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium.
Not available
S-EPMC10819943 | biostudies-literature
Sort   by:  
 Page size